Clinical Trial Update: EP0057 in Combination With Olaparib in Advanced Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for EP0057 in combination with olaparib in advanced ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• EP0057 (camptothecin nanoparticle formulation)
• Olaparib (Olaparib)

Snippet

Sponsor: Ellipses Pharma | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED